{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:56:06Z","timestamp":1783997766906,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Early recognition, diagnosis, and treatment of this progressive, multisystem disease by enzyme replacement therapy (ERT) can lead to improved outcomes and reduced mortality.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This report documents the diagnostic journey and treatment with ERT of three siblings with MPS IVA. Clinical outcome measures included growth, endurance, imaging, cardiac, respiratory, ophthalmology, and laboratory evaluations.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Three siblings, diagnosed at 14.7, 10.1, and 3.2\u00a0years of age, demonstrated clinical improvement with weekly infusions of 2.0\u00a0mg\/kg elosulfase alfa (Vimizim<jats:sup>\u00ae<\/jats:sup>, BioMarin Pharmaceutical, Novato, CA, USA). Patient 1 (oldest sibling) and Patient 2 (middle sibling) experienced a diagnostic delay of 8\u00a0years 7\u00a0months and 4\u00a0years after symptom onset, respectively. All three patients demonstrated improvements in growth, 6-min walk distance, joint range of motion, and respiratory function after 30\u00a0months of ERT. The treatment was well tolerated without any adverse events.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This case series highlights the importance of early recognition of the clinical and imaging findings that are initially subtle in MPS IVA. Early treatment with ERT is necessary to slow irreversible disease progression and improve patient outcomes. The oldest sibling experienced improvements in mobility despite severe symptoms resulting from a late diagnosis. When evaluating patients with skeletal anomalies, imaging multiple body regions is recommended. When findings such as anterior beaking of vertebrae or bilateral femoral head dysplasia are present, MPS IVA should be included in the differential diagnosis. Newborn screening must be considered for early detection, accurate diagnosis, and initiation of treatment to reduce morbidity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01618-y","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T14:04:26Z","timestamp":1606745066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-9804","authenticated-orcid":false,"given":"Can","family":"Ficicioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena R.","family":"Matalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Luongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Menello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Kornafel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Degnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"issue":"1","key":"1618_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI. Recommendations for the management of MPS IVA: systematic evidence-and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1618_CR2","first-page":"141","volume":"12","author":"S Tomatsu","year":"2014","unstructured":"Tomatsu S, Yasuda E, Patel P, Ruhnke K, Shimada T, Mackenzie WG, Mason R, Thacker MM, Theroux M, Monta\u00f1o AM. Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev. 2014;12(1):141.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"3","key":"1618_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2013.04.009","volume":"109","author":"E Yasuda","year":"2013","unstructured":"Yasuda E, Fushimi K, Suzuki Y, Shimizu K, Takami T, Zustin J, Patel P, Ruhnke K, Shimada T, Boyce B. Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab. 2013;109(3):301\u201311.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1618_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S0006-291X(74)80446-8","volume":"61","author":"R Matalon","year":"1974","unstructured":"Matalon R, Arbogast B, Dorfman A. Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux\u2013Lamy syndrome. Biochem Biophys Res Commun. 1974;61(4):1450\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"suppl_5","key":"1618_CR5","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50(suppl_5):v4\u201312.","journal-title":"Rheumatology"},{"issue":"1","key":"1618_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, Guffon N, Burton BK, Hendriksz CJ, Mitchell J, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54\u201361.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"1618_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10545-012-9459-0","volume":"36","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Al-Jawad M, Berger KI, Hawley SM, Lawrence R, Mc Ardle C, Summers CG, Wright E, Braunlin E. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36(2):309\u201322.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1618_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10545-013-9587-1","volume":"36","author":"TC Wood","year":"2013","unstructured":"Wood TC, Harvey K, Beck M, Burin MG, Chien Y-H, Church HJ, D\u2019Almeida V, van Diggelen OP, Fietz M, Giugliani R. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36(2):293\u2013307.","journal-title":"J Inherit Metab Dis"},{"key":"1618_CR9","unstructured":"BioMarin Pharmaceutical Inc. Vimizim\u00ae (elosulfase alfa) [prescribing information]; 2014."},{"key":"1618_CR10","unstructured":"BioMarin Pharmaceutical Inc. Vimizim\u00ae (elosulfase alfa) [summary of product characteristics]; 2014."},{"issue":"6","key":"1618_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, Lin SP, Mengel E, Scarpa M, Valayannopoulos V, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37(6):979\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"1618_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/pr.2015.169","volume":"78","author":"SA Jones","year":"2015","unstructured":"Jones SA, Bialer M, Parini R, Martin K, Wang H, Yang K, Shaywitz AJ, Harmatz P. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y. Pediatr Res. 2015;78(6):717\u201322.","journal-title":"Pediatr Res"},{"issue":"4","key":"1618_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ymgme.2011.08.029","volume":"104","author":"M Furujo","year":"2011","unstructured":"Furujo M, Kubo T, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab. 2011;104(4):597\u2013602.","journal-title":"Mol Genet Metab"},{"key":"1618_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgmr.2017.08.007","volume":"13","author":"M Furujo","year":"2017","unstructured":"Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up. Mol Genet Metab Rep. 2017;13:69\u201375.","journal-title":"Mol Genet Metab Rep"},{"key":"1618_CR15","first-page":"249","volume":"2018","author":"DR Matalon","year":"2018","unstructured":"Matalon DR, Dougherty P, Lulis L, Medne L, Krantz I, Yum S, Ficicioglu C. The diagnosis and natural history of mucopolysaccharidosis IVA in one family. Mol Genet Metab. 2018;2018:249\u201350.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01618-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01618-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01618-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T14:05:26Z","timestamp":1606745126000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01618-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01618-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Parental consent was obtained to use the patients\u2019 medical data, photographs, and videos.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Parental consent was obtained to publish the patient\u2019s medical data, photographs, and videos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Can Ficicioglu, MD, PhD, has served as an advisor or consultant for: Genzyme, Horizon, Orphan Tech., Recordati, Shire, and Sobi. He received grants for clinical research from: Genzyme, Orphan Tec, RegenxBio, Takeda, and Vtesse. Dena R. Matalon, MD, none. Nicole Luongo, PA-C, none. Caitlin Menello, CGC,, none. Tracy Kornafel,, none. Andrew J. Degnan, MD, none.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"336"}}